Search Results - Pollyea, D.A.

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Current Diagnosis Patterns for Acute Myeloid Leukemia: Concordance Between Clinical Practice (Connect® Disease Registry) and Who 2008 Recommendations

    Current Diagnosis Patterns for Acute Myeloid Leukemia: Concordance Between Clinical Practice (Connect® Disease Registry) and Who 2008 Recommendations by George, T.I, Erba, H.P, Pollyea, D.A, Abedi, M, Roboz, G.J, Thompson, M.A, Fliss, A, Swern, A.S, Nifenecker, M, Kiselev, P, Sugrue, M.M, Foucar, K

    Published in Leukemia research
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)

    Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) by Stein, E.M, Fathi, A.T, DiNardo, C.D, Pollyea, D.A, Swords, R.T, Roboz, G.J, Collins, R, Sekeres, M.A, Stone, R.M, Attar, E.C, Tosolini, A, Xu, Q, Amatangelo, M, Gupta, I, Knight, R.D, de Botton, S, Tallman, M.S, Kantarjian, H.M

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

    1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive adva... by Pollyea, D.A, de Botton, S, Fathi, A.T, Stein, E.M, Tallman, M.S, Agresta, S, Bowden, C, Fan, B, Prah, M, Yang, H, Yen, K, Stone, R.M

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    170 - Current Diagnosis Patterns for Acute Myeloid Leukemia: Concordance Between Clinical Practice (Connect® Disease Registry) and Who 2008 Recommendations

    170 - Current Diagnosis Patterns for Acute Myeloid Leukemia: Concordance Between Clinical Practice (Connect® Disease Registry) and Who 2008 Recommendations by George, T.I., Erba, H.P., Pollyea, D.A., Abedi, M., Roboz, G.J., Thompson, M.A., Fliss, A., Swern, A.S., Nifenecker, M., Kiselev, P., Sugrue, M.M., Foucar, K.

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    38 - Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS)

    38 - Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) by Stein, E.M., Fathi, A.T., DiNardo, C.D., Pollyea, D.A., Swords, R.T., Roboz, G.J., Collins, R., Sekeres, M.A., Stone, R.M., Attar, E.C., Tosolini, A., Xu, Q., Amatangelo, M., Gupta, I., Knight, R.D., de Botton, S., Tallman, M.S., Kantarjian, H.M.

    Published in Leukemia research
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    PS1500 HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) TREATED IN THE CONNECT® MDS/AML DISEASE REGISTRY

    PS1500 HEALTHCARE RESOURCE UTILIZATION (HCRU) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA (AML) TREATED IN THE CONNECT® MDS/AML DISEASE REGISTRY by Mukherjee, S., Abedi, M., Erba, H.P., Pollyea, D.A., Roboz, G.J., Thompson, M.A., Louis, C.U., Flick, E.D., Nifenecker, M., Kiselev, P., Swern, A.S., Cogle, C.R.

    Published in HemaSphere
    Request full text
    Article
    Save to List
    Saved in:
  7. 7
    PS1025 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT NEWLY‐DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

    PS1025 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT NEWLY‐DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION... by Roboz, G.J., DiNardo, C.D., Stein, E.M., Botton, S., Mims, A.S., Prince, G.T., Altman, J.K., Arellano, M.L., Donnellan, W., Erba, H.P., Mannis, G.N., Pollyea, D.A., Stein, A.S., Uy, G.L., Watts, J.M., Fathi, A.T., Kantarjian, H.M., Tallman, M.S., Choe, S., Dai, D., Fan, B., Wang, H., Zhang, V., Yen, K.E., Kapsalis, S.M., Hickman, D., Liu, H., Agresta, S., Wu, B., Attar, E.C., Stone, R.M.

    Published in HemaSphere
    Request full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: